COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Active, not recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

June 15, 2025

Conditions

Hypertrophic Cardiomyopathy (HCM)

Interventions

DRUG

Approved Hypertrophic Cardiomyopathy drug treatments

As per product label

DRUG

Mavacamten

As per product label

Trial Locations (1)

IQVIA, Durham